Wed Sep 18 02:19:00 UTC 2024: ## Neuralink’s Vision-Restoring Implant Receives FDA Breakthrough Designation
**San Francisco, CA** – Elon Musk’s neurotechnology company, Neuralink, announced that its experimental brain implant designed to restore vision, known as Blindsight, has received the U.S. Food and Drug Administration’s (FDA) breakthrough device designation. This designation is given to medical devices that hold the potential to treat or diagnose life-threatening conditions and is designed to accelerate their development and review.
Musk stated that Blindsight could enable even those who have lost both eyes and their optic nerve to see. The device, which is implanted within the skull, processes and transmits neural signals to devices like computers or phones. While Neuralink has not yet disclosed a timeline for human trials, the FDA’s designation suggests the device is moving closer to clinical testing.
This latest development follows Neuralink’s ongoing research on a separate implant designed to allow paralyzed patients to control digital devices through thought. This device, currently being tested on three patients, is expected to take several years to complete its trial phase.
Neuralink, founded in 2016 by Elon Musk, is dedicated to creating brain-computer interfaces with the goal of helping individuals with disabilities regain mobility, communication, and sensory abilities. The company’s groundbreaking work continues to attract attention and raise hopes for the future of neurotechnology.
First Piper 